Beranda › Leukemia Mieloid Akut › Arkansas
Uji klinis Leukemia Mieloid Akut di Arkansas
13 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi di Arkansas.
Kota di Arkansas
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Menerima pesertaFase 2
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Arkansas at Little Rock, Little Rock
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Arkansas for Medical Sciences, Little Rock
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Menerima pesertaFase 2
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Arkansas Children's Hospital, Little Rock
Menerima pesertaFase 3
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Arkansas Children's Hospital, Little Rock
Menerima pesertaFase 3
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Arkansas Children's Hospital, Little Rock
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Arkansas Children's Hospital, Little Rock
Menerima pesertaFase 3
29 Days – 21 Years · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Arkansas Children's Hospital, Little Rock
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Arkansas Children's Hospital, Little Rock
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT05101551Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.